Cardiovascular

Therapies for heart disease, stroke, and vascular conditions including novel lipid-lowering and anti-thrombotic agents.

Companies

Pipeline Drugs

577

Key People

827

Cardiovascular Pipeline (577 drugs)

Commercial: 148Approved: 123Phase 3: 48Approved/Commercial: 41Phase 1: 29Phase 2: 29Preclinical: 15Pre-clinical: 13Phase 1/2: 10Various: 9Development: 8Phase 2/3: 7Not Specified: 6Research: 5ANDA Filed/Development: 4Discovery: 4Platform/Tool Development: 3Development/Registration: 2Preclinical/Discovery: 2Late-Stage Clinical (Pivotal): 2Undisclosed: 2ANDA Filed/Approved: 2Device Development: 2Phase 3-ready: 2Commercial/Diagnostic: 2FDA-Cleared: 2Various (Typically Phase 2-4): 2Commercial (Post-market): 2Phase 3 (IDE): 2Acquisition: 1Phase 1-3: 1Phase 3/Commercial: 1Commercial/Filed: 1Development to Commercial: 1Approved / Filed: 1Phase (Partnered): 1Approved/Registration: 1Phase 1 to Commercial: 1Pre-clinical to Filing: 1Pivotal: 1Approved & Development: 1Pre-Approval: 1Approved/Filed: 1Regulatory Review: 1Clinical Study: 1Phase 3 / Commercial: 1Non-GMP / Research: 1Filed/Development: 1Filed/Approved: 1Discovery to Preclinical: 1Early Feasibility Study: 1Phase 1/2a: 1Clinical Trials: 1Clinical Evaluation: 1Research & Development: 1Clinical/Regulatory: 1Phase II: 1Phase I: 1Phase 1b/2: 1Phase 1b: 1Discovery/Research: 1Pre-clinical to Phase 3: 1Approved (CE Mark): 1Investigational: 1Approved (China NMPA Review): 1Clinical-stage: 1Pre-clinical/Discovery: 1FDA Breakthrough Device Designation: 1Pre-Clinical: 1Implementation: 1Phase 1b/2a: 1Screening/Diagnostic: 1Various (Typically Phase 3): 1Early-Stage (FIH/EFS): 1Early Clinical Development: 1First-in-Human (FIH): 1R&D: 1Clinical Development: 1Platform Technology: 1Registry: 1

Drug	Company	Indication	Phase	Status
Tirzepatide (Mounjaro)	Eli Lilly	Type 2 Diabetes	Approved	Commercial
Tirzepatide (Zepbound)	Eli Lilly	Obesity	Approved	Commercial
Donanemab	Eli Lilly	Alzheimer's Disease	Phase 3	Regulatory Review
Mirikizumab	Eli Lilly	Ulcerative Colitis	Phase 3	Active
Lebrikizumab	Eli Lilly	Atopic Dermatitis	Phase 3	Active
Orforglipron	Eli Lilly	Type 2 Diabetes	Phase 3	Active
Pirtobrutinib	Eli Lilly	B-cell Malignancies	Phase 3	Active
Retifanlimab	Eli Lilly	Various Cancers	Phase 2/3	Active
Verzenio (abemaciclib)	Eli Lilly	Breast Cancer	Approved	Commercial
Jardiance (empagliflozin)	Eli Lilly	Diabetes/Heart Failure	Approved	Commercial
Trulicity (dulaglutide)	Eli Lilly	Type 2 Diabetes	Approved	Commercial
Taltz (ixekizumab)	Eli Lilly	Psoriasis	Approved	Commercial
Emgality (galcanezumab)	Eli Lilly	Migraine	Approved	Commercial
Patisiran (ONPATTRO)	Alnylam Pharmaceuticals	Hereditary Transthyretin Amyloidosis	Approved	Commercial
Givosiran (GIVLAARI)	Alnylam Pharmaceuticals	Acute Hepatic Porphyria	Approved	Commercial
Lumasiran (OXLUMO)	Alnylam Pharmaceuticals	Primary Hyperoxaluria Type 1	Approved	Commercial
Inclisiran (LEQVIO)	Alnylam Pharmaceuticals	Hypercholesterolemia	Approved	Commercial - Partnered
Vutrisiran	Alnylam Pharmaceuticals	Hereditary Transthyretin Amyloidosis	Phase 3	Active
ALN-AGT01	Alnylam Pharmaceuticals	Hypertension	Phase 1	Active
ALN-KHK	Alnylam Pharmaceuticals	Primary Hyperoxaluria	Phase 3	Active
ALN-APP	Alnylam Pharmaceuticals	Alzheimer's Disease	Phase 1	Active
Cemdisiran	Alnylam Pharmaceuticals	C5 Complement-mediated Diseases	Phase 2	Active
BGE-102	BioAge Labs	Cardiovascular Risk and Metabolic Dysfunction	Phase 1	Active
APJ Program	BioAge Labs	Obesity	Preclinical	Active
Tagrisso (osimertinib)	AstraZeneca	EGFR-mutated lung cancer	Approved	Commercial
Imfinzi (durvalumab)	AstraZeneca	Various cancers	Approved	Commercial
Lynparza (olaparib)	AstraZeneca	BRCA-mutated cancers	Approved	Commercial
Calquence (acalabrutinib)	AstraZeneca	Blood cancers	Approved	Commercial
Farxiga (dapagliflozin)	AstraZeneca	Diabetes/Heart failure/CKD	Approved	Commercial
Brilinta (ticagrelor)	AstraZeneca	Cardiovascular disease	Approved	Commercial
Symbicort	AstraZeneca	Asthma/COPD	Approved	Commercial
Breztri	AstraZeneca	COPD	Approved	Commercial
Forxiga	AstraZeneca	Type 2 diabetes	Approved	Commercial
Crestor (rosuvastatin)	AstraZeneca	High cholesterol	Approved	Commercial
Keytruda (pembrolizumab)	Merck	Multiple Cancer Types	Commercial	Active
Gardasil/Gardasil 9	Merck	HPV Prevention	Commercial	Active
Lenvima (lenvatinib)	Merck	Thyroid/Liver/Kidney Cancer	Commercial	Active
CORTONE (cortisone)	Merck	Rheumatoid Arthritis	Commercial	Active
Streptomycin	Merck	Tuberculosis	Commercial	Historical
Sulfaquinoxaline (S.Q.)	Merck	Animal Health - Coccidiosis	Commercial	Active
Cosentyx®	Novartis	Pediatric Hidradenitis Suppurativa (12+)	Approved	FDA Approved March 2026
Pan-mutant-selective PI3Kα inhibitor	Novartis	Breast Cancer	Acquisition	Under acquisition
Stelara (ustekinumab)	Johnson & Johnson	Psoriasis, Crohn's Disease, Ulcerative Colitis	Approved	Commercial
Darzalex (daratumumab)	Johnson & Johnson	Multiple Myeloma	Approved	Commercial
Imbruvica (ibrutinib)	Johnson & Johnson	Blood Cancers	Approved	Commercial
Tremfya (guselkumab)	Johnson & Johnson	Psoriasis, Psoriatic Arthritis	Approved	Commercial
Erleada (apalutamide)	Johnson & Johnson	Prostate Cancer	Approved	Commercial
JNJ-4528 (CAR-T)	Johnson & Johnson	Multiple Myeloma	Phase 3	Active
JNJ-6372	Johnson & Johnson	Lung Cancer	Phase 2	Active
Nipocalimab	Johnson & Johnson	Myasthenia Gravis	Phase 3	Active